Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 10 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Prostate-Specific Antigen Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Prostate Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Serum Medicine & Life Sciences
Digital Rectal Examination Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1998 2011

PHASE III TRIAL OF SELENIUM FOR PROSTATE CANCER PREVENT

Ahmann, F. R. & Marshall, J.

National Institutes of Health

9/30/9910/31/11

Project: Research projectResearch Project

Selenium
Prostatic Neoplasms
Incidence
Biopsy
Prostate

PHASE II CHEMOPREVENTION TRIAL OF SE AND PROSTATE CANCER

Ahmann, F. R., Marshall, J. & Clark, L.

National Institutes of Health

9/30/988/31/09

Project: Research projectResearch Project--Cooperative Agreements, Research Project

Chemoprevention
Selenium
Prostatic Neoplasms
Therapeutics
Watchful Waiting

Research Output 1979 2017

  • 4100 Citations
  • 29 h-Index
  • 84 Article
  • 4 Chapter
3 Citations

Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men

Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. L. A., Scardino, P. T., Flanigan, R. C., DeKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. & Southwick, P. C. Feb 1 2017 In : Journal of Urology. 197, 2, p. S200-S207

Research output: Research - peer-reviewArticle

Digital Rectal Examination
Prostate-Specific Antigen
Early Detection of Cancer
Multicenter Studies
Prostatic Neoplasms
37 Citations

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer

Algotar, A. M., Stratton, M. S., Ahmann, F. R., Ranger-Moore, J., Nagle, R. B., Thompson, P. A., Slate, E., Hsu, C. H., Dalkin, B. L., Sindhwani, P., Holmes, M. A., Tuckey, J. A., Graham, D. L., Parnes, H. L., Clark, L. C. & Stratton, S. P. Feb 15 2013 In : Prostate. 73, 3, p. 328-335 8 p.

Research output: Research - peer-reviewArticle

Phase III Clinical Trials
Selenium
Prostatic Neoplasms
Placebos
Prostate-Specific Antigen
77 Citations

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

Tolcher, A. W., Quinn, D. I., Ferrari, A., Ahmann, F., Giaccone, G., Drake, T., Keating, A. & De Bono, J. S. Apr 2012 In : Annals of Oncology. 23, 4, p. 968-973 6 p.

Research output: Research - peer-reviewArticle

Castration
Prostatic Neoplasms
taxane
docetaxel
Prostate-Specific Antigen
1 Citations

Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity

Algotar, A. M., Thompson, P. A., Ranger-Moore, J., Stratton, M. S., Hsu, C. H., Ahmann, F. R., Nagle, R. B. & Stratton, S. P. Apr 2012 In : Internal Medicine Journal. 42, 4, p. 374-380 7 p.

Research output: Research - peer-reviewArticle

Prostate-Specific Antigen
Prostatic Neoplasms
Aspirin
Smoking
Odds Ratio
57 Citations
Prostatectomy
Prostatic Neoplasms
Placebos
polyphenon E
Polyphenols